201 related articles for article (PubMed ID: 24584382)
1. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome.
Rahman MZ; Ahmed DS; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Barua R; Ishaque SM
Mymensingh Med J; 2014 Jan; 23(1):105-13. PubMed ID: 24584382
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
[TBL] [Abstract][Full Text] [Related]
3. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.
Chapman ND; Grillage MG; Mazumder R; Atkinson SN
Br J Clin Pract; 1990 Nov; 44(11):461-6. PubMed ID: 2177997
[TBL] [Abstract][Full Text] [Related]
4. [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome].
Zhong YQ; Zhu J; Guo JN; Yan R; Li HJ; Lin YH; Zeng ZY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):899-902. PubMed ID: 18261269
[TBL] [Abstract][Full Text] [Related]
5. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
Kennedy TM; Chalder T; McCrone P; Darnley S; Knapp M; Jones RH; Wessely S
Health Technol Assess; 2006 Jun; 10(19):iii-iv, ix-x, 1-67. PubMed ID: 16729918
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].
Kang SH; Jeen YT; Koo JS; Koo YS; Kim KO; Kim YS; Kim SY; Moon JS; Park JJ; Baek IH; Park SC; Lee SJ; Lee JH; Choung RS; Choi SC
Korean J Gastroenterol; 2013 Nov; 62(5):278-87. PubMed ID: 24262593
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
Darvish-Damavandi M; Nikfar S; Abdollahi M
World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021
[TBL] [Abstract][Full Text] [Related]
8. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome.
Dumitraşcu DL; Stănculete M
Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606
[TBL] [Abstract][Full Text] [Related]
9. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.
Reme SE; Kennedy T; Jones R; Darnley S; Chalder T
J Psychosom Res; 2010 Apr; 68(4):385-8. PubMed ID: 20307706
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study.
Alam MS; Roy PK; Miah AR; Mollick SH; Khan MR; Mahmud MC; Khatun S
Mymensingh Med J; 2013 Jan; 22(1):27-30. PubMed ID: 23416804
[TBL] [Abstract][Full Text] [Related]
11. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome.
Lüttecke K
Curr Med Res Opin; 1980; 6(6):437-43. PubMed ID: 6988171
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study.
Goettsch WG; van den Boom G; Breekveldt-Postma NS; Smout AJ; Herings RM
Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):803-10. PubMed ID: 15386693
[TBL] [Abstract][Full Text] [Related]
13. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
14. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome.
Van Outryve M; Mayeur S; Meeus MA; Rosillon D; Hendrickx B; Ceuppens M
J Clin Pharm Ther; 1995 Oct; 20(5):277-82. PubMed ID: 8576295
[TBL] [Abstract][Full Text] [Related]
15. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
Kennedy T; Jones R; Darnley S; Seed P; Wessely S; Chalder T
BMJ; 2005 Aug; 331(7514):435. PubMed ID: 16093252
[TBL] [Abstract][Full Text] [Related]
16. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
Everitt HA; Moss-Morris RE; Sibelli A; Tapp L; Coleman NS; Yardley L; Smith PW; Little PS
BMC Gastroenterol; 2010 Nov; 10():136. PubMed ID: 21087463
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.
Kountouras J; Chatzopoulos D; Zavos C; Boura P; Venizelos J; Kalis A
Hepatogastroenterology; 2002; 49(43):193-7. PubMed ID: 11941952
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China.
Hou X; Chen S; Zhang Y; Sha W; Yu X; Elsawah H; Afifi AF; El-Khayat HR; Nouh A; Hassan MF; Fatah AA; Rucker Joerg I; Sánchez Núñez JM; Osthoff Rueda R; Jurkowska G; Walczak M; Malecka-Panas E; Linke K; Hartleb M; Janssen-van Solingen G
Clin Drug Investig; 2014 Nov; 34(11):783-93. PubMed ID: 25258162
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine.
El-Haggar SM; Hegazy SK; Abd-Elsalam SM; Bahaa MM
Biomed Pharmacother; 2022 Jan; 145():112399. PubMed ID: 34775240
[TBL] [Abstract][Full Text] [Related]
20. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.
Everitt H; Moss-Morris R; Sibelli A; Tapp L; Coleman N; Yardley L; Smith P; Little P
BMC Gastroenterol; 2013 Apr; 13():68. PubMed ID: 23602047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
